Reveris Therapeutics

Biotech · Private

Small molecule CIB1 inhibitors for triple negative breast cancer

Grants
$800K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Developing therapeutic inhibitors of CIB1 for breast cancer$300,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Developing therapeutic inhibitors of CIB1 for breast cancer$400,000
Federal grantDepartment of Health and Human Services · Phase I · Developing therapeutic inhibitors of CIB1 for breast cancer$100,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1141PROTON BIO, INC.——
1142REZIGENE, LLC——
1143Optivia Biotechnology Inc.——
1144Reveris Therapeutics——
1145IATERION, INC.——
1146RAZI PHARMA LLC——
1147Character Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.